Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans

Phase 1 Completed 6 enrolled Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

NaSingle-groupOpen-labelHealth-services research

Summary

To assess absorption, metabolism and excretion of \[14C\]-LXI-15028 in Chinese healthy male Subjects following a single oral dose of \[14C\]LXI-15028 suspension.

Timeline

Start: 2022-06-30
Primary completion: 2022-07-21
Completion: 2022-12-23

Publications

Bian Y, Yuan J, Ma S, Nan J, Gu Z, Feng H, Yu Z, Liu Z, Xie F, Wang Y, Liu C, Zhang H, Miao L. Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using 14C-radiolabelled techniques. Expert Opin Drug Metab Toxicol. 2025 Jul;21(7):897-907. doi: 10.1080/17425255.2025.2505637. Epub 2025 May 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tegoprazan	Other / unclassified	50 mg	Oral

Indications

No indication recorded.